Loading clinical trials...
Loading clinical trials...
A Phase 2B Randomized, Placebo Controlled, Double Blind Clinical Trial of EPI-743 in Children With Leigh Syndrome
Conditions
Interventions
Placebo
EPI-743 15 mg/kg
+1 more
Locations
4
United States
Stanford University
Palo Alto, California, United States
Akron Children's Hospital
Akron, Ohio, United States
Baylor College of Medicine
Houston, Texas, United States
Seattle Children's Hospital
Seattle, Washington, United States
Start Date
October 31, 2012
Primary Completion Date
February 28, 2015
Completion Date
May 31, 2015
Last Updated
August 31, 2020
NCT05554835
NCT06967831
NCT03137355
Lead Sponsor
PTC Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions